Abstract: Objective To evaluate the efficacy and safety of low molecular weight Heparin（LMWH） combined with Edaravone injection for progressive cerebral infarction（PCI）. Methods Randomized controlled trials （RCTs） of LMWH combined with Edaravone injection treating PCI were identified with CNKI, CBM, VIP, Wanfang, PubMed, MEDLINE, and EMBASE databases up to April 2012, we also scanned references of all included studies and pertinent reviews, compared to LMWH alone for PCI. Every research was evaluated, and then analyzed with Revman 5.0.0 software. Result Eleven randomized controlled trials were included, among total 867 PCI patients, 434 were in trial group and the other 433 were in control group, all evaluation of methodology were graded C. As the meta-analysis showed, the differences of the clinic efficiency rate and effective rate between the two groups were significant, the RR （95%CI） were: 1.64（1.43,1.88）、 0.70（0.55, 0.89）, respectively. The difference was not statistically significant, compared with two groups of treatment of nerve function defect score. After treatment, weighted mean difference and 95%CI were: -5.45（-6.59, -4.31）, the differences were statistically significant. Adverse reactions between the two groups were not statistically significant, its RR and 95%CI were: 2.14 （0.89, 5.14）. Conclusion LMWH combined with Edaravone injection therapy might be more effective than LMWH alone for PCI. However, the results should be interpreted with caution because of the low quality of the included studies. Two groups of security were not significantly different. High-quality, large-scale RCTs are needed to further prove the results.